Skip to Content

Merck & Co Inc MRK Stock Quote

| Rating as of


Market Open

| Currency in USD

  • Last Close 107.31
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Blend
  • Day Range 106.42  –  107.88
  • Year Range 84.52  –  119.65
  • Market Cap 272.8597 Bil
  • Volume / Avg 1.3 Mil /  7.2 Mil
  • Price / Sales 4.68
  • Price / Book 7.04
  • Forward Div Yield 2.60%
  • Trailing Div Yield 2.72%

Morningstar‘s Stock Analysis MRK

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Merck: Increasing Fair Value Based on Improving Pipeline

Damien Conover Sector Director

Analyst Note

| Damien Conover |

Following a review of Merck's pipeline, we are increasing our fair value estimate to $103 from $97 based on slightly increased projections for several pipeline drugs, including pulmonary arterial hypertension, or PAH, drug sotatercept, which has shown excellent efficacy and continues to look well-positioned versus the competitive landscape. Phase 3 data presented earlier in the year was exceptionally strong, with an 84% reduction in death or clinical worsening. With the current PAH market close to $6 billion annually, we believe sotatercept can complement current therapies well and expand the overall market. While current drugs are helpful in managing the disease, the five-year mortality rate is close to 40%, according to Reveal study data, showing the need for new therapies. We expect sotatercept will gain approval in 2024. Beyond sotatercept, we remain optimistic for several other pipeline drugs, including cancer drugs V940, favezelimab, vibostolimab, and quavonlimab, which should all post important additional clinical data over the next three years. The strong and growing late-stage pipeline reaffirms our view of Merck's wide moat.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics MRK

Company Profile MRK

Business Description

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

126 East Lincoln Avenue
Rahway, NJ, 07065
Industry Drug Manufacturers - General
Employees 69,000

Related Articles MRK

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of MRK’s competitive advantage.

Merck & Co Inc


Bristol-Myers Squibb Co


Eli Lilly and Co


Pfizer Inc

+$0.08 (0.08%) +$0.27 (0.46%) −$23.02 (4.04%) −$0.28 (0.82%)
Market Cap
272.86 Bil123.34 Bil518.62 Bil188.26 Bil
Drug Manufacturers - General Drug Manufacturers - General Drug Manufacturers - General Drug Manufacturers - General

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Merck & Co Inc Stock

Yes. MRK has a forward dividend yield of 2.72%. See MRK’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

MRK’s market cap is 272.86 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

MRK’s stock style is Large Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

MRK’s price/sales is 4.68.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

MRK’s price/forward earnings is 87.96.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

MRK’s price/book is 7.04.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See MRK’s valuation ratios compared to the Market Index.

MRK’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare MRK’s historical performance against its industry peers and the overall market.